171 related articles for article (PubMed ID: 35753770)
1. Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era.
Izumo T; Awano N; Kuse N; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Ota H; Inomata M
Drug Discov Ther; 2022 Jul; 16(3):124-127. PubMed ID: 35753770
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
[TBL] [Abstract][Full Text] [Related]
3. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series.
Cicchitto G; Cardillo L; Sequino D; Sabatini P; Adamo L; Marchitiello R; Viscardi M; Cozzolino L; Cavallera A; Bocchino M; Sanduzzi Zamparelli A; Ferrigno F; de Carlo E; de Martinis C; Fusco G
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680143
[TBL] [Abstract][Full Text] [Related]
5. Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.
Chesdachai S; Rivera CG; Cole KC; Teaford HR; Gonzalez Suarez ML; Larsen JJ; Ganesh R; Tulledge-Scheitel S; Razonable RR
Sci Rep; 2024 Mar; 14(1):5430. PubMed ID: 38443438
[TBL] [Abstract][Full Text] [Related]
6. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Falci DR; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Hebner CM; Sager J; Mogalian E; Tipple C; Peppercorn A; Alexander E; Pang PS; Free A; Brinson C; Aldinger M; Shapiro AE;
N Engl J Med; 2021 Nov; 385(21):1941-1950. PubMed ID: 34706189
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
Viruses; 2023 May; 15(6):. PubMed ID: 37376600
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
9. [Sotrovimab in controlling SARS-CoV-2 infection].
Płusa T
Pol Merkur Lekarski; 2022 Feb; 50(295):48-50. PubMed ID: 35278299
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO).
Tuan JJ; Sharma M; Kayani J; Davis MW; McManus D; Topal JE; Ogbuagu O
BMC Infect Dis; 2023 Apr; 23(1):258. PubMed ID: 37101135
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes.
Wong G; Rowlandson M; Sabanayagam D; Ginn AN; Kable K; Sciberras F; Au E; Draper J; Arnott A; Sintchenko V; Dwyer DE; Chen SCA; Kok J
Transplantation; 2022 Sep; 106(9):1860-1866. PubMed ID: 35675438
[TBL] [Abstract][Full Text] [Related]
12. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
13. Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study.
Woo MS; Brehm TT; Fischer M; Heyer A; Wichmann D; Jordan S; Nörz D; Lütgehetmann M; Addo MM; Lohse AW; Schmiedel S; Kluge S; Schulze Zur Wiesch J
Microbiol Spectr; 2023 Feb; 11(1):e0410322. PubMed ID: 36475890
[No Abstract] [Full Text] [Related]
14. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.
Patel V; Levick B; Boult S; Gibbons DC; Drysdale M; Lloyd EJ; Singh M; Birch HJ
BMC Infect Dis; 2024 Apr; 24(1):428. PubMed ID: 38649824
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge.
Bartalucci C; Limongelli A; Nicolini LA; Ponzano M; Tigano S; Farinella ST; Carrega G; Malerba G; Magnè F; Balletto E; Giacobbe DR; Riccio G; Cenderello G; Taramasso L; Bruzzone B; Vena A; Di Biagio A; Mikulska M; De Maria A; Dentone C; Bassetti M
J Chemother; 2024 Jul; 36(4):283-290. PubMed ID: 38095569
[TBL] [Abstract][Full Text] [Related]
16. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
17. Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events.
Yoshida J; Shiraishi K; Tanaka M
BMC Infect Dis; 2022 Dec; 22(1):902. PubMed ID: 36461006
[TBL] [Abstract][Full Text] [Related]
18. Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.
Lo CKL; Lo CKF; Komorowski AS; Leung V; Matic N; McKenna S; Perez-Patrigeon S; Sheth PM; Lowe CF; Chagla Z; Bai AD
BMC Res Notes; 2024 Jan; 17(1):37. PubMed ID: 38267971
[TBL] [Abstract][Full Text] [Related]
19. Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.
Gliga S; Lübke N; Killer A; Gruell H; Walker A; Dilthey AT; Thielen A; Lohr C; Flaßhove C; Krieg S; Pereira JV; Seraphin TP; Zaufel A; Däumer M; Orth HM; Feldt T; Bode JG; Klein F; Timm J; Luedde T; Jensen BO
Clin Infect Dis; 2023 Feb; 76(3):408-415. PubMed ID: 36189631
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
